Plain-English translation of NCT07304271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether paclitaxel — a cancer-fighting drug delivered directly into your abdominal cavity — combined with standard chemotherapy can help people with gastric cancer that has spread to the lining of the abdomen (peritoneum) live longer. Currently, patients with this type of cancer receive chemotherapy through the bloodstream, but it doesn't always reach the abdomen well enough. This study compares the new combination approach to standard chemotherapy alone.
Gastric cancer that spreads to the abdomen is very serious, and current treatments don't work as well as doctors would like partly because standard chemotherapy doesn't reach the abdominal lining effectively. Researchers believe delivering this medication directly to the affected area could improve survival and give patients better outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either standard chemotherapy alone or standard chemotherapy combined with the medication delivered directly into your abdomen. You will continue treatment until your cancer progresses, you experience unacceptable side effects, or the study ends. Throughout your participation, you will have regular clinic visits for monitoring, blood tests, and scans to track how well the treatment is working. The study team will follow you for as long as clinically possible to measure how the treatment affects your survival.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
Italy
Netherlands
Sweden